Condition: Severe Hemophilia A · Sponsor: Octapharma
Recombinant factor VIII for the prevention of bleeding in patients with severe haemophilia A undergoing major surgery while receiving emicizumab prophylaxis
This description comes directly from the study's public registry record.
Sigurd Knaub, PhD · +41 554512141 · Sigurd.Knaub@octapharma.com
Always discuss trial participation with your own doctor first.
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| University Hospital Centre Zagreb | Zagreb, Croatia | Recruiting |
| Helsinki University Hospital | Helsinki, Finland | Recruiting |
| CHU de Nantes Hôtel-Dieu | Nantes, France | Recruiting |
| CHRU de Tours | Tours, France | Recruiting |
| Vivantes Klinikum im Friedrichshein (KFH) | Berlin, Germany | Recruiting |
| Gerinnungszentrum Rhein-Ruhr | Duisburg, Germany | Recruiting |
| Universitätsklinikum Hamburg Eppendorf (UKE) | Hamburg, Germany | Recruiting |
| Christian Medical College Vellore | Vellore, Tamil Nadu, India | Recruiting |
| St. John's Medical College Hospital | Bengaluru, India | Recruiting |
| Azienda Ospedaliera Pugliese Ciaccio | Catanzaro, Italy | Recruiting |
| Azienda Ospedaliero Universitaria Careggi - Centro Emofilia | Florence, Italy | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05935358